SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

BACKGROUND: Despite the promise of dual BRAF/MEK inhibition as a therapy for BRAF-mutant (BRAF-mut) melanoma, heterogeneous responses have been observed in patients, thus predictors of benefit from therapy are needed. We have previously identified semaphorin 6A (SEMA6A) as a BRAF-mut-associated prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Loria, Rossella, Laquintana, Valentina, Scalera, Stefano, Fraioli, Rocco, Caprara, Valentina, Falcone, Italia, Bazzichetto, Chiara, Di Martile, Marta, Rosanò, Laura, Del Bufalo, Donatella, Bossi, Gianluca, Sperduti, Isabella, Terrenato, Irene, Visca, Paolo, Soddu, Silvia, Milella, Michele, Ciliberto, Gennaro, Falcioni, Rita, Ferraresi, Virginia, Bon, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016967/
https://www.ncbi.nlm.nih.gov/pubmed/35440004
http://dx.doi.org/10.1186/s13046-022-02354-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016967/
https://www.ncbi.nlm.nih.gov/pubmed/35440004
http://dx.doi.org/10.1186/s13046-022-02354-w

Ejemplares similares